Clinical Trial Update: Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing predictive biomarkers of response to sunitinib in poorly differentiated neuroendocrine tumors; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Pancreatic Neoplasms

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Status: TERMINATED